Long-term survival in a young woman with recurrent HER2-positive breast cancer.

Lungosopravvivenza in giovane donna affetta da tumore mammario recidivato HER2-positivo

Authors

  • Gianluca Cotroneo UOC Oncologia Medica, ASST Bergamo Est, Seriate (BG) - Italy

DOI:

https://doi.org/10.19156/abtpn.2018.0035

Keywords:

Lapatinib, Trastuzumab, Pertuzumab, Breast cancer, Long-term survival

Abstract

We report the case of a patient with HER2-positive breast cancer relapsing after 7 years from diagnosis with a HER2-positive tumor recurrence, treated with anti-HER2 drugs (pertuzumab, trastuzumab and lapatinib) associated to radiotherapy and/or chemotherapy. These therapeutic strategies allowed satisfactory disease control after about 4 years from recurrence (Oncology).

Downloads

Download data is not yet available.

Downloads

Published

2018-06-27

How to Cite

Cotroneo, G. (2018). Long-term survival in a young woman with recurrent HER2-positive breast cancer.: Lungosopravvivenza in giovane donna affetta da tumore mammario recidivato HER2-positivo. AboutOpen, 4(1), 29–31. https://doi.org/10.19156/abtpn.2018.0035

Issue

Vol. 4 No. 1 (2018): January - December 2018

Section

Case report

License

Authors contributing to AboutOpen agree to publish their articles under the Creative Commons NonCommercial 4.0 International License (CC BY-NC 4.0), which allows third parties to copy and redistribute the material providing appropriate credit and a link to the license but does not allow to use the material for commercial purposes and to use the material if it has been remixed, transformed or built upon. 

Metrics

Crossref
Scopus
Google Scholar
Europe PMC